Geranial (Citral A): An Encyclopedic Reference
1. Identity and Chemical Characterization
1.1 Names and Identifiers
Geranial — also known as citral A, trans-citral, or α-citral — is an acyclic monoterpenoid aldehyde. Its systematic IUPAC name is (2E)-3,7-dimethylocta-2,6-dienal. The CAS numbers relevant to this compound are 5392-40-5 for citral (the mixture), 106-26-3 for neral, and 141-27-5 for geranial specifically. Additional synonyms appearing in the chemical literature include geranialdehyde, 3,7-dimethyl-2,6-octadien-1-al, and FEMA number 2303.
Geranial does not exist in isolation in nature; it is one of two geometric (cis/trans) isomers that together constitute citral. Citral is an acyclic monoterpenoid aldehyde consisting of two geometrical isomers: geranial (citral A, trans-citral, or the E-isomer) and neral (citral B, cis-citral, or the Z-isomer), typically found in an approximate 3:2 ratio. Because geranial and neral are always found co-occurring in nature and are analytically inseparable in most botanical oils, the scientific literature overwhelmingly studies them jointly as "citral," with geranial being the dominant and, in most bioassays, more pharmacologically potent of the two.
1.2 Molecular Structure and Physical Properties
Structurally, citral (C₁₀H₁₆O) is an acyclic monoterpene aldehyde, and its chemical attributes make it a key component in several essential oils. Geranial has a boiling point of 118–119 °C at 2.7 kPa, a density (d20) of 0.8888, and a refractive index (n20 D) of 1.4898. Citral occurs as a pale yellow liquid with a strong lemon odour; it is insoluble in water but soluble in ethanol, diethyl ether, and mineral oil. Both isomers are insoluble in water and share a density of 0.891–0.897 at 15 °C.
In practical terms, geranial is the more potent of the two isomers with a strong, sharp lemon odor, while neral is softer and slightly sweeter. Because citral is an α,β-unsaturated aldehyde with an additional double bond, it is highly reactive and may undergo reactions such as cyclization and polymerization. This reactivity is directly relevant to both its biological mechanisms and its safety profile.
Citral is also used as a precursor for the production of ionone and vitamin A. Geraniol, citronellol, and 3,7-dimethyloctan-1-ol can be obtained from citral by stepwise hydrogenation, highlighting its significance as an industrial chemical precursor.
1.3 Biosynthesis in Plants
The formation of citral in plants has been reported to involve the enzymatic oxidation of geraniol and/or nerol to citral by enzymes belonging to the NADP-dependent alcohol dehydrogenases (ADHs) class. It has been recently demonstrated that citral formation in lemongrass is catalyzed by two phylogenetically distant enzymes — a dual-localized CfADH1 (present in both the cytosol and plastids) and a cytosol-localized CfAKR2b — both of which utilize geraniol as a substrate to produce citral.
2. Natural Sources and Botanical Origins
2.1 Primary Plant Sources
Citral (3,7-dimethyl-2,6-octadienal) is a monoterpene aldehyde that represents a mixture of cis and trans isomers. The major source (65%–85%) is an essential oil isolated from lemongrass (Cymbopogon citratus) leaves, but it can also be found in Citrus spp. Citral is found in litsea cubeba oil (about 80%), lemongrass oil (80%), clove basil oil (65%), sour lemon oil (35%), and lemon oil.
Additional citral-bearing botanical sources include:
- Cymbopogon species from India and Sri Lanka contain high concentrations of citral. Litsea cubeba from China is another major commercial source. Lemon myrtle plantations in Australia also yield citral-rich oils.
- Citral is also found in a wide diversity of plant leaves and fruits, such as limes, oranges, lemons, tomatoes, myrtle trees, and African basil.
- Lemon balm (Melissa officinalis), in which geranial (citral A, trans-citral) constitutes 20–35% of the essential oil, and neral (citral B, cis-citral) constitutes 15–25%.
- Lemon verbena (Aloysia citrodora), noted by Encyclopaedia Britannica as a natural source of citral.
- Zingiber officinale (ginger) also contains these isomers: GC/MS analysis identified neral and geranial constituting 30–40% of a steam-distilled ginger extract.
The proportion of geranial to neral within a given plant source is not fixed. It varies according to the geographical origin, geobotanical conditions of the environment, farming practices, plant age, photoperiod, harvest period, genetic differences, and the extraction methods. For instance, in one lemongrass (Cymbopogon citratus) oil analysis, geranial was 42.78% and neral was 32.82% of the total oil.
2.2 Commercial and Industrial Forms
In commerce, geranial is encountered primarily as a component of citral (the two-isomer mixture), rather than as an isolated compound. Most commercial citral is a blend of both isomers, with the ratio between them varying depending on the natural source or the synthetic production method. Commercial preparations include:
- Natural lemongrass essential oil, produced by steam distillation, which captures powerful compounds present in the plant, especially citral, the main component responsible for its lemony smell.
- Isolated natural citral, derived from Litsea cubeba, lemongrass (Cymbopogon citratus or C. flexuosus), or lemon myrtle by fractional distillation of the essential oil.
- Synthetic citral, produced on a large scale. Synthetic production involves manufacturing citral from petrochemical feedstocks including isobutylene and formaldehyde.
- Microencapsulated citral, a form used in food science and in some pharmacological investigations to improve stability and controlled release, as referenced in NTP toxicology studies.
3. Traditional and Historical Use
3.1 South Asian Traditions (Ayurveda)
The most extensively documented traditional use of geranial-rich plants is that of lemongrass in Ayurveda. In Ayurveda, India's traditional treatment system, lemongrass essential oil (LGEO) treats hypertension, fever, stomach disease, and inflammation related to rheumatism, colds, and flu. Lemongrass essential oil has been used since ancient times in folk medicine as a remedy to improve circulation, stabilise menstrual cycles, promote digestion, or increase immunity.
In ancient India and China, lemongrass was widely used in Ayurvedic and traditional Chinese medicine to treat digestive issues, fever, infections, and inflammation. It was also believed to have detoxifying and calming effects, often brewed into teas or applied as an herbal remedy.
Preparations used historically include decoctions (aqueous infusions of fresh or dried leaf), steam inhalation, poultices, and topically applied oil blends. Traditional use shifted over time from ritual bathing to more clinical applications: poultices for headaches, decoctions for fever and dysentery, and inhalations for congestion. Ayurvedic practitioners traditionally harvested the fresh stalks and leaves, steam-distilled them to extract oil, or dried them under shade to preserve volatile constituents; only the aerial parts — leaves and inflorescences — were used, as roots were generally ignored in classical texts.
3.2 African and Afro-Brazilian Traditions
Traditional uses of citral-rich plants in ethnopharmacology, particularly in Asia, Africa, and South America, have long underpinned their application in managing symptoms of inflammation. Lippia alba, a lemongrass-related plant rich in citral, is widely used in folk medicine across Latin America. Lippia alba is empirically used in infusions, teas, macerates, and hydroalcoholic extracts because of its antispasmodic, analgesic, sedative, and anxiolytic effects.
Over time, medicinal use of lemongrass spread across the Middle East and Africa, where it became an important part of folk medicine and natural healing practices. By the 15th and 16th centuries, lemongrass was introduced to Europe and the Caribbean through trade routes, where it gained popularity for its essential oil extraction and perfumery uses.
3.3 Caribbean and Southeast Asian Traditions
Thai cuisine and traditional medicine have employed lemongrass for centuries, both as a culinary flavoring agent and as a digestive remedy. Caribbean folk medicine traditions valued lemongrass tea as a calming beverage and fever reducer, often combining it with ginger and other local herbs to create comprehensive wellness formulas. Traditional practitioners prepared lemongrass tea to address bloating, indigestion, and stomach cramps, recognizing its carminative properties long before modern research confirmed these effects.
In the 19th and 20th centuries, lemongrass became a key ingredient in aromatherapy and natural insect repellents due to its high citral content.
4. Key Constituents, Active Compounds, and Context within Source Plants
When geranial is discussed as a natural ingredient, it is inseparable from the broader phytochemical matrix of the plants that contain it. In lemongrass essential oil, for example, the major constituents alongside geranial include:
- The major component is citral (a mixture of neral and geranial) ranging from 70.6% to 79.0% in some Lippia alba studies; oxygenated monoterpenes found include linalool (1.7%–2.2%), nerol (0.5%–2.5%), geraniol (0.8%–2.0%), and geranyl acetate (0.8%–1.4%).
- The antibacterial activity of lemongrass essential oil is attributed to the presence of active components including citral, citronellal, citronellol, linalool, and geraniol.
While geranial is the dominant phytochemical driver of many of the properties attributed to lemongrass and related oils, the biological effects of the whole oil often involve synergistic contributions from multiple monoterpenes. The present article focuses specifically on geranial and citral (as the inseparable mixture), given that virtually all mechanistic and clinical research has been conducted on citral or geranial/neral in combination.
5. Mechanisms of Action
5.1 Antimicrobial Mechanisms
The antimicrobial activity of citral, in which geranial is the dominant and more potent isomer, operates through multiple membrane and intracellular mechanisms. At low concentrations, an aldehyde can cross-link amino groups in the cell wall and cytoplasm and inhibit enzymes with a thiol group in the cytoplasmic membrane. Citral in high concentrations could target the cytoplasm, causing coagulation and precipitation of cytoplasmic components. At intermediate concentrations, aldehydes can also cause cytoplasmic clotting. Unsaturated alpha- and beta-aldehydes have a broad antimicrobial spectrum and show similar activity against Gram-positive and Gram-negative microorganisms.
5.2 Antifungal Mechanisms
For fungal targets specifically, geranial appears to disrupt membrane integrity via interference with ergosterol biosynthesis. Research showed that geranial exhibited larger inhibition zones, higher cellular leakage rates, and increased membrane-damaged conidia compared to neral. Furthermore, geranial possessed more promising ergosterol biosynthesis inhibition effects than neral, and both induced synthesis of 7-Dehydrodesmosterol and Cholesta-5,7,22,24-tetraen-3β-ol, which are marker sterols when ERG6 is affected. These results suggest geranial is more potent than neral against T. rubrum, and both inhibit ergosterol biosynthesis by affecting ERG6.
Ergosterol is necessary for maintaining cell membrane integrity and permeability; its abnormal reduction or absence leads to cellular leakage resulting in fungal death, and its synthetic process is a potential drug target for the development of novel antifungal agents.
5.3 Anti-Inflammatory Mechanisms
Citral has been shown to modulate key inflammatory pathways, including the inhibition of COX-2 and NF-κB, reduction of pro-inflammatory cytokines, and activation of peroxisome proliferator-activated receptors (PPARs). More specifically, the anti-inflammatory mechanism of citral is attributed to the inhibition of NF-κβ signaling; citral activates peroxisome proliferator-activated receptor (PPAR-γ) and inhibits IκB phosphorylation, which independently blocks NF-κβ activity with the consequent inhibition of gene expression of inflammatory mediators.
These molecular actions support citral's ability to alleviate inflammation in various systems, including respiratory, gastrointestinal, neuroinflammatory, and orofacial conditions.
5.4 Antiproliferative and Apoptotic Mechanisms
Studies show that citral effectively inhibits the proliferation of cancer cells in in vitro models. This effect has been associated with the capacity of this bioactive compound to induce apoptosis and cause cell cycle arrest via induction of ROS production, modification of the expression of the Bcl-2 family proteins and p53, and regulation of MAPK, NF-κB, PI3K-Akt, and AMPαK signaling pathways. However, to consider it as a candidate for the development of cancer therapy, it is necessary to evaluate the effectiveness of this metabolite using in vivo cancer models.
A critical finding that distinguishes geranial from its isomer neral is its relative potency: in studies evidencing the potential antiproliferative activity of geranial, neral, and citral, geranial (the E-isomer) was found to be the most effective, being seven-fold more active than neral. The treatment of leukemic cells with citronellal or geranic acid did not lead to procaspase-3 processing or DNA fragmentation, indicating that the α,β-unsaturated aldehyde group is crucial for these processes — a structural finding that specifically highlights the aldehyde moiety of geranial as essential for its cytotoxic activity.
5.5 Neurological Mechanisms
Citral, as a mixture of trans-geranial and cis-neral, is the main constituent of Lippia alba essential oil and possesses analgesic, anxiolytic, anticonvulsant, and sedative effects. The mechanism of peripheral analgesic/sedative action has been demonstrated in preclinical models: studies evaluated the effects of Lippia alba essential oil and citral on compound action potentials (CAPs) in Wistar rat sciatic nerves; both drugs inhibited CAP in a concentration-dependent manner, with a calculated half-maximal inhibitory concentration (IC₅₀) of 35.00 µg/mL (or 230 µM) for citral.
6. Scientific Evidence by Area of Use
6.1 Antimicrobial Activity
Evidence strength: Moderate (robust in vitro; limited in vivo; no clinical trials for geranial alone)
Citral has exhibited a broad spectrum of biological activities, where it has been described as an effective antimicrobial agent against different Gram-positive and Gram-negative bacteria, fungi, and parasites of clinical relevance. In one well-cited PMC study examining lemongrass essential oil against dual-species biofilms, the MIC of lemongrass essential oil against planktonic C. albicans, C. tropicalis, and S. aureus were 0.0781%, 0.039%, and 0.0781%, respectively; the MIC of citral against C. albicans, C. tropicalis, and S. aureus were 0.0313%, 0.0156%, and 0.0313%, respectively.
Regarding food preservation applications, investigations have demonstrated that this compound exhibits several biological activities, such as antibacterial, antifungal, antibiofilm, antiparasitic, antiproliferative, anti-inflammatory, and antioxidant properties, by in vitro and in vivo assays. Additionally, when incorporated into different food matrices, citral can reduce the microbial load of pathogenic microorganisms and extend the shelf life.
Critically, this compound has acceptable drug-likeness properties and does not present any violations of Lipinski's rules, which could be used for drug development. However, all antimicrobial evidence for geranial itself remains at the preclinical (in vitro and animal) stage. No clinical trials examining geranial or citral as standalone therapeutic antimicrobials in human patients had been identified in the literature reviewed.
6.2 Antifungal Activity
Evidence strength: Moderate in vitro; preliminary in vivo; no human clinical data for geranial specifically
Research showed that geranial exhibited larger inhibition zones (p < 0.01 or 0.05), higher cellular leakage rates (p < 0.01), and increased conidia with damaged membranes (p < 0.01) within 24 h, more distinct shriveled mycelium in SEM, and prominent cellular material leakage in TEM. Furthermore, geranial possessed more promising ergosterol biosynthesis inhibition effects than neral; both induced synthesis of 7-Dehydrodesmosterol and Cholesta-5,7,22,24-tetraen-3β-ol, marker sterols when ERG6 is affected. These results suggest geranial is more potent than neral against T. rubrum, and both inhibit ergosterol biosynthesis by affecting ERG6.
A separate PMC-indexed study in Frontiers in Microbiology demonstrated that citral has been illustrated to exhibit strong antifungal activities against P. digitatum, P. italicum, and Geotrichum citri-aurantii. In one study, citral was found to inhibit the mycelial growth of P. digitatum in a dose-dependent manner with a minimum inhibitory concentration (MIC) of 2.0 µL/mL and a minimum antifungal concentration (MFC) of 4.0 µL/mL.
Citral has promising antifungal activities and ergosterol biosynthesis inhibition effects against several pathogenic fungi; however, no study had yet focused on neral and geranial separately against T. rubrum, which hinders their clinical application.
6.3 Anti-Inflammatory Activity
Evidence strength: Preclinical (animal and in vitro); no well-designed human clinical trials identified for isolated geranial
Citral exhibits a broad range of anti-inflammatory effects through various molecular pathways. It inhibits key enzymes like COX-2, reducing prostaglandin production, and modulates NF-κB activity, which plays a critical role in cytokine production. Citral also activates peroxisome proliferator-activated receptors (PPARs), which further contribute to its anti-inflammatory action.
Despite growing evidence supporting the pharmacological potential of citral, several challenges hinder its full therapeutic application. Key issues include gaps in mechanistic understanding, limitations in clinical translation, and concerns regarding safety and bioavailability.
The anti-inflammatory evidence base consists primarily of cell-culture models and rodent studies. The literature reviewed for this article did not identify randomized controlled trials in human subjects for geranial or citral administered as isolated compounds in an anti-inflammatory context.
6.4 Antiproliferative and Potential Anticancer Activity
Evidence strength: Preliminary (in vitro and limited in vivo animal data); no human clinical evidence
The PMC literature identifies multiple in vitro studies across various cancer cell lines. In leukemia models, citral induced apoptosis in leukemia cell lines including U937 and HL60; treatment for 4–24 h with citral (45 µM) resulted in an activation of the enzymatic activity of caspase-3, which is essential for apoptotic processes.
In breast cancer models, an in vitro study with breast cancer MCF-7 cells demonstrated the ability of citral to dramatically reduce the proliferation of these tumor cells, especially 48 and 72 h after treatment (IC50-48 h = 18 µM). The results suggest that the antiproliferative effect is not related to necrosis cell death induction, but apoptosis at low concentrations. Another mechanism by which citral presented an antiproliferative effect on MCF-7 was induction of cell cycle arrest in the G2/M phase.
In prostate cancer models, citral showed important antiproliferative activity on PC-3 and PC3M cells in vitro; the monoterpene induced cell detachment, modified the morphology of cancer cells, and suppressed lipogenesis in prostate cancer cells. Molecular interaction studies predicted that citral isomers (geranial and neral) interact with proteins involved in lipogenesis and the apoptosis pathway. Citral suppressed lipogenesis of prostate cancer cells by activation of AMPK phosphorylation and downregulation of different enzymes, including fatty acid synthase, acetyl-CoA carboxylase, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
In stomach cancer (gastric cancer) cells, a transcriptome analysis using RNA-seq explored citral's capability to persuade apoptosis in AGS human stomach cancer cell lines in vitro; enrichment and KEGG pathway results suggested that several genes are involved in inducing the apoptosis pathway. The study also demonstrated that citral arrested colony formation and migration of cancer cells significantly compared to untreated cells.
In an in vivo mouse model, BALB/c mice were challenged with 4T1 breast cancer cells followed by daily oral feeding of 50 mg/kg citral or distilled water for two weeks. Citral did not cause evident toxicity as specified by body weight at the end of the treatments. In addition, tumors in citral-treated mice injected with 4T1 cells were found to be reduced four times in size compared to controls.
A further nanoparticle formulation study reported that of the two isomers, geranial was more effective in controlling in vivo tumor growth. Retro-orbital injection of nanoparticles containing geranial at three doses of 80 mg/kg resulted in approximately 92% reduction in tumor volume compared to controls that received unloaded nanoparticles. While there was significant reduction in tumor volume, even high doses of nanoparticles loaded with citral, neral, or geranial did not cause noticeable toxicity in the animals.
However, to consider citral as a candidate for cancer therapy, it is necessary to evaluate the effectiveness of this metabolite using in vivo cancer models, and human clinical trials are entirely absent from the current literature. All anticancer claims remain at the preclinical stage and should not be interpreted as clinical evidence of efficacy.
6.5 Anxiolytic and Sedative Activity
Evidence strength: Preclinical and animal studies; limited controlled human data for citral specifically
Citral (a mixture of geranial and neral, monoterpene aldehydes) is found in lemon and lemongrass oils and has demonstrated anxiolytic activity in both animal and human studies. In a zebrafish anxiety model, the aim was to investigate the anxiolytic properties of C. citratus essential oil, hydroalcoholic extract, citral, geraniol, and the mixture of these terpenoids, as well as their possible mechanism of action; adult zebrafish were treated by immersion.
Preclinical studies using plant sources rich in citral have demonstrated significant antioxidant, anti-inflammatory, antimicrobial, anxiolytic, and potential anticancer effects, with these activities mainly linked to secondary metabolites such as verbascoside and citral, which influence oxidative stress, inflammation, and apoptosis-related pathways. Despite these promising results, clinical evidence remains limited.
6.6 Analgesic and Peripheral Nerve Effects
Evidence strength: Preclinical (in vitro nerve preparations and animal models)
Studies evaluated the effects of the essential oil of Lippia alba and citral on compound action potentials (CAPs) in Wistar rat sciatic nerves. Both drugs inhibited CAP in a concentration-dependent manner. The calculated IC₅₀ of peak-to-peak amplitude was 53.2 µg/mL for the essential oil and 35.00 µg/mL (or 230 µM) for citral. Peak-to-peak amplitude of the CAP was significantly reduced by 30 µg/mL of Lippia alba essential oil and 10 µg/mL citral; both drugs (at 60 and 30 µg/mL, respectively) significantly increased chronaxy and rheobase.
6.7 Antioxidant Activity
Evidence strength: In vitro and limited in vivo; mechanism reasonably characterized
Citral epigenetically modulates DNA, increasing the activity of endogenous antioxidant enzymes, while inhibiting enzymes involved in lipid peroxidation. Analyzed studies demonstrated the protective capacity of citral and citrus essential oil in cells stressed by hydrogen peroxide and excess glucose in the medium. Moreover, citral has antimicrobial, anti-inflammatory, and antimutagenic activity that can be exploited in cell culture.
7. Body Systems and Health Areas Associated with Geranial
- Immune and Infectious Disease: Antibacterial activity against Gram-positive and Gram-negative pathogens; antifungal activity against Candida spp., Trichophyton rubrum, and food spoilage molds; antibiofilm properties.
- Inflammatory Pathways: Inhibition of COX-2, NF-κB, and reduction of pro-inflammatory cytokines; activation of PPAR-γ, with potential relevance to respiratory, gastrointestinal, and orofacial inflammation.
- Oncology (preclinical only): Antiproliferative and pro-apoptotic activity across leukemia, breast cancer, prostate cancer, stomach cancer, and endometrial cancer cell lines; all evidence is in vitro or animal-based.
- Central and Peripheral Nervous System: Anxiolytic and sedative properties observed in animal models; peripheral nerve conduction blockade relevant to analgesia.
- Digestive System: Traditional carminative and antispasmodic use; no confirmed mechanism at the isolated geranial level from human clinical studies.
- Integumentary System: Antifungal and antibacterial activity relevant to skin and nail infections in vitro; contact sensitization potential is an established concern (see safety section).
- Metabolic/Lipid Pathways (preclinical): Suppression of lipogenesis in cancer cells via AMPK phosphorylation and downregulation of fatty acid synthase.
8. Regulatory Status and GRAS Classification
Citral is a monoterpene constituted by two isomers, neral and geranial. It is present in different plant sources and recognized as safe (GRAS) by the Food and Drug Administration (FDA). The FDA includes citral in its list of substances considered Generally Recognized as Safe as a synthetic flavoring substance. The Flavor and Extract Manufacturers Association (FEMA) Expert Panel has reviewed the safety of citral and determined that it is GRAS for use as a flavoring substance.
The regulatory picture differs internationally. Although the FDA includes citral in its list of substances considered GRAS, it is included in the European list of "allergenic" substances. Citral is included in the EU 26 list of potential cosmetic allergens. The EU Cosmetic Regulation requires that the presence of any of the 26 allergens, including citral, be listed in the ingredient list if their concentration exceeds 0.001% in leave-on products or 0.01% in rinse-off products.
9. Dosage Forms and Dosages Reported in Studies
Because geranial is not commercially sold as an isolated dietary supplement (it is encountered as a component of citral or within essential oils), dosage information derives exclusively from research contexts. The following represents dosages as stated in published studies:
- In vitro cancer cell lines: Citral at 45 µM for 4–24 hours resulted in caspase-3 activation in leukemia cell lines.
- In vitro breast cancer (MCF-7): An IC50 of 18 µM at 48 h was reported in MCF-7 breast cancer cells.
- In vitro endometrial cancer: Citral, a mixture of neral and geranial, inhibited the proliferation of Ishikawa and ECC-1 cells at an IC50 of 10 µM (2.3 µg/mL).
- In vivo mouse breast cancer (oral administration): BALB/c mice were challenged with 4T1 breast cancer cells followed by daily oral feeding of 50 mg/kg citral or distilled water for two weeks.
- In vivo mouse breast cancer (nanoparticle, retro-orbital injection): Retro-orbital injection of nanoparticles containing geranial at three doses of 80 mg/kg resulted in approximately 92% reduction in tumor volume compared to controls that received unloaded nanoparticles.
- Peripheral nerve blockade (ex vivo rat sciatic nerve): The calculated IC50 of peak-to-peak amplitude was 35.00 µg/mL (or 230 µM) for citral.
- Antifungal (in vitro, Penicillium digitatum): Citral inhibited mycelial growth in a dose-dependent manner with a minimum inhibitory concentration (MIC) of 2.0 µL/mL and a minimum antifungal concentration (MFC) of 4.0 µL/mL.
- Antifungal (in vitro, Candida and S. aureus): MIC of citral against C. albicans, C. tropicalis, and S. aureus were 0.0313%, 0.0156%, and 0.0313%, respectively.
No standardized therapeutic dosage for human administration of geranial as an isolated compound has been established in a clinical guideline, pharmacopeia, or regulatory monograph reviewed for this article.
10. Safety Considerations and Known Interactions
10.1 Skin Sensitization (Contact Allergy)
The most well-documented safety concern for geranial and citral is dermal sensitization. The IFRA Standard restricts the use of citral in fragrances because of potential sensitization. The core concern with citral is contact sensitization, meaning repeated exposure can trigger allergic reactions in a subset of people even at low concentrations. Citral is associated with allergies and contact dermatitis.
Both neral and geranial were reported as moderate skin sensitisers, based on Local Lymph Node Assay (LLNA) responses for oxidation products of air-exposed geraniol. Geranial and neral gave EC3 values of 0.45 M (or 6.8%) and 0.64 M (or 9.7%), respectively.
Data from patch-testing in human dermatitis patients are instructive: a total of 1,476 dermatitis patients with suspected allergic contact dermatitis were patch tested using geranial, neral, and citral (all 3.5% petrolatum). Frequencies of positive reactions to citral, geranial, and neral were 2.9%, 3.4%, and 1.9%, respectively. Importantly, skin sensitization was induced in 22/174 tests conducted with 1–5% pure citral in ethanol, but not with 0.5% citral in 82 test subjects.
Cross-reactivity is a relevant concern: sensitivity to citral often overlaps with issues around geraniol, hydroxycitronellal, and citrus peel extracts. Exposure to air, light, or heat can oxidize citral into more reactive compounds, raising the odds of dermatitis.
10.2 IFRA Concentration Limits
The maximum acceptable use limits calculated for citral using the dermal sensitisation Quantitative Risk Assessment (QRA) by IFRA were: 0.05% in deodorants, 0.6% in hydroalcoholic products for unshaved skin, 7% in liquid soaps, 8.2% in shampoos, and 100% in baby diapers and hand dishwashing. IFRA subsequently changed these limits to 5% for liquid soaps and shampoos and 2.5% for baby diapers and hand dishwashing as maximum pragmatic levels for practical management.
EU law requires brands to disclose citral whenever it exceeds 0.001% in leave-on products or 0.01% in rinse-off products.
10.3 Eye and Respiratory Irritation
Citral/geranial is classified under GHS as an eye irritant (Category 2) and a skin irritant (Category 2) as well as a skin sensitizer (Category 1) based on regulatory hazard classifications. Aerosolized citral, as in sprays or diffusers, can trigger coughing fits in reactive users even if skin tolerance seems fine.
10.4 Phototoxicity
Data provided citral a No Expected Sensitization Induction Level (NESIL) of 1,400 µg/cm² for the skin sensitization endpoint. The phototoxicity and photoallergenicity endpoints were evaluated based on data and ultraviolet (UV) spectra; citral is not expected to be phototoxic or photoallergenic.
10.5 Genotoxicity and Systemic Toxicity
Citral is not genotoxic. Data on citral provide a calculated margin of exposure greater than 100 for repeated dose toxicity and developmental and reproductive toxicity endpoints. The chemicals are not expected to cause severe effects with repeated oral exposures at levels relevant to use as a food flavoring.
Because of its particular aroma, substantial antibacterial, antifungal, and insecticidal effects, as well as its low toxicity and low carcinogenicity, citral is classified as a substance that is "Generally Recognized as Safe" (GRAS) and has been widely used as a food additive and fragrance material in cosmetics.
10.6 Bioavailability Challenges
Despite growing evidence supporting the pharmacological potential of citral, several challenges hinder its full therapeutic application. Key issues include gaps in mechanistic understanding, limitations in clinical translation, and concerns regarding safety and bioavailability. Geranial's chemical instability — its susceptibility to oxidation, cyclization, and polymerization — creates formulation challenges for pharmaceutical development and may limit systemic exposure following oral or topical administration. This is one driver behind investigation of nanoparticle delivery systems in cancer research.
10.7 Interactions
No well-documented pharmacokinetic drug–drug interactions specific to isolated geranial were identified in the peer-reviewed sources reviewed. The broader class of monoterpene aldehydes may interact with cytochrome P450 enzymes and thiol-containing proteins due to their α,β-unsaturated aldehyde reactivity, a property explicitly implicated in both antimicrobial and pro-apoptotic mechanisms. However, this has not been systematically characterized in human pharmacokinetic studies for geranial specifically.
11. Evidence Summary and Research Gaps
Geranial, primarily studied as a component of citral, has an extensive in vitro evidence base demonstrating antimicrobial, antifungal, anti-inflammatory, and antiproliferative properties. Its mechanisms of action — ranging from membrane disruption to NF-κB and COX-2 inhibition to caspase-3 activation — are reasonably well-characterized at the cellular and molecular level. In vivo animal data support its anticancer and anti-inflammatory activity at defined doses. However, as of the sources available for this article:
- No randomized controlled clinical trials in human subjects have evaluated geranial or citral as standalone therapeutic agents for any indication.
- All antiproliferative (cancer-related) evidence is restricted to cell culture and rodent models.
- Long-term effects of citral exposure on human health and the environment remain poorly characterized. Future research could focus on in-depth mechanistic studies, the development of citral-based combination therapies, and long-term safety assessments. Such investigations would expand understanding of citral and facilitate its sustainable and efficient application in various sectors.
References
Go back